Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 12/20 | 0.66 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375797 | 0.92 | KIF11 (0.66) | KIF11SLC22A12CA1CA2PTGS2 | |
| SCHEMBL4662560 | 0.84 | KIF11 (0.68) | KIF11SLC22A12ALOX5APFEN1 | |
| SCHEMBL4661074 | 0.83 | KIF11 (0.66) | KIF11SLC22A12CA1CA2PTGS2 | |
| SCHEMBL4661255 | 0.82 | KIF11 (0.58) | KIF11CA1CA2PTGS2IKBKB | |
| SCHEMBL3380022 | 0.80 | KIF11 (1.00) | KIF11SLC22A12CA1CA2NR3C2 | |
| SCHEMBL3378328 | 0.79 | KIF11 (0.75) | KIF11SLC22A12ALOX5APFEN1 | |
| SCHEMBL4662605 | 0.79 | KIF11 (0.68) | KIF11SLC22A12 | |
| SCHEMBL3378781 | 0.79 | KIF11 (0.68) | KIF11SLC22A12 | |
| SCHEMBL13656086 | 0.78 | KIF11 (0.89) | KIF11CA1CA2NR3C2 | |
| SCHEMBL3375971 | 0.78 | KIF11 (0.66) | KIF11SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694281-A4 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070259951-A1 | Compounds, Compositions and Methods | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | US | disclosed |
| EP-1694281-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005060692-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259951-A1 | Compounds, Compositions and Methods | ALPP, PCNA, MKI67 | KIF11 824/4885SLC22A12 3290/4885CA1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.